EN DE
Check 40,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

20/20 Biolabs, Inc. (AIDX) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of 20/20 Biolabs, Inc. stock $0.20, price $0.20, upside +3.1%, quality 38 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

22 20/20 Biolabs, Inc. logo Thin data Nov 10, 2026

20/20 Biolabs, Inc.

AIDX · US
Low Priority

The stock costs about what our calculation considers fair.

Revenue last quarter +37% vs. a year ago.
Fair value $0.2017 · Fairly valued
Negative equity (buybacks among others)
Mixed vs. peers (4/7)
Quality 38/100
Weak Growth (revenue 5y −2.6 %/yr in USD)
Loss-making · -182.8% net margin (FY2025)
Negative free cash flow
Narrow moat 12/100
Thin data
Estimate

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$23.85 $0.1869 Fair Value $0.2017 Feb 2026 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

9‑month range $0.1869 – $23.85 · fair‑value band $0.1513 – $0.2522 · the $0.1956 price screens below the $0.2017 fair value. As of Nov 10, 2026.

Follow 20/20 Biolabs, Inc. Common Stock in your weekly email

Every Wednesday you see whether 20/20 Biolabs, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers.

Show moreShow less

It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025.

The company was incorporated in 2000 and is based in Gaithersburg, Maryland.

Stock analysis

20/20 Biolabs, Inc. (AIDX) currently trades at $0.1956, while our estimate is $0.2017, so the stock looks roughly fairly valued today (gap 3.0%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.1513 (bear) to $0.2522 (bull), the price of $0.1956 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

20/20 Biolabs, Inc. Common Stock reported revenue of $2.0M in FY2025 versus $9.6M in FY2021, a compound −32.1%/yr. Reported net income was −$3.7M in FY2025.

Key figures

Market cap $2.9M Micro · P/S ratio 1.43 · EPS (TTM) $−0.7500 · Return on equity −331% · Return on assets (EBIT) −44.8% (5-year average) · Operating margin −170% · Revenue (TTM) $2.0M · Revenue growth (YoY) +36.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at 3%, AIDX screens richer than that median.

Fair Value

Bear $0.1513 Fair Value $0.2017 Bull $0.2522
Price $0.1956 · Upside +3.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 50
Do the profits arrive as real cash?
Financial strength 46
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+16.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−43.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.6%
Start year 2020 (pandemic). Over 10 years: +14.2% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−87.1% (2020) → −162.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch AIDX, get fair value alerts →

Compare 20/20 Biolabs, Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 38 · Below median
Fair Value upside +3.1% · Above median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −0.1% · Above median
Net margin (12 months) −182.8% · Bottom 25%
Operating margin (12 months) −170.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 36.5% · Top 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 1.43× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)37 · sector 17
FUTURE (revenue growth)100 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 34

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs AIDX
DexCom, Inc DXCM $79.92 $89.18 +12% vs AIDX
Stryker Corporation SYK $324.29 $358.30 +10% vs AIDX
STERIS plc STE $257.12 $279.53 +9% vs AIDX
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs AIDX
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs AIDX
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs AIDX
Abbott Laboratories, ABT $110.46 $75.28 −32% vs AIDX
Medtronic plc MDT $101.59 $65.61 −35% vs AIDX
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs AIDX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

20/20 Biolabs, Inc. Common Stock: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "20/20 Biolabs, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/AIDX

Frequently asked questions

Is 20/20 Biolabs, Inc. (AIDX) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.2017 versus a price of $0.1956, about +3% upside (fairly valued).
What is the fair value of AIDX?
Our estimate for 20/20 Biolabs, Inc. is $0.2017 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.1956.
What is the quality score of AIDX?
20/20 Biolabs, Inc. has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for 20/20 Biolabs, Inc. (AIDX)?
Our calculated price target is the estimate of $0.2017 (as of Nov 10, 2026). Cautious scenario $0.1513, optimistic scenario $0.2522. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the 20/20 Biolabs, Inc. Common Stock stock forecast for 2026?
Our estimate puts fair value at $0.2017, about +3% upside versus a price of $0.1956 (fairly valued). Cautious scenario $0.1513, optimistic scenario $0.2522. The calculation is refreshed regularly with new filings.
What is the revenue of 20/20 Biolabs, Inc. (AIDX)?
20/20 Biolabs, Inc. reported trailing-twelve-month revenue of about $2.0M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of 20/20 Biolabs, Inc. (AIDX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For 20/20 Biolabs, Inc. it is $0.2017 per share (as of Nov 10, 2026), against a price of $0.1956.
Is 20/20 Biolabs, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Nov 10, 2026, AIDX trades below its calculated fair value: price $0.1956, fair value $0.2017, a gap of about +3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AIDX?
No. The price is what the market pays today ($0.1956); the fair value is what the company's own numbers justify ($0.2017). For 20/20 Biolabs, Inc. the two are $0.0061 per share apart. That gap is exactly why we show both numbers side by side.
How much is 20/20 Biolabs, Inc. Common Stock worth?
The market values 20/20 Biolabs, Inc. at about $2.9M (market capitalisation, as of Nov 10, 2026). Per share that is $0.1956; our models calculate a fair value of $0.2017 per share.
What do the bullish and bearish scenarios say about AIDX?
Our models span a range for 20/20 Biolabs, Inc.: cautious scenario $0.1513, base $0.2017, optimistic $0.2522 per share (as of Nov 10, 2026, price $0.1956). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of 20/20 Biolabs, Inc. (AIDX)?
Balance-sheet figures for 20/20 Biolabs, Inc. (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
Which stocks are comparable to 20/20 Biolabs, Inc. Common Stock?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is 20/20 Biolabs, Inc. Common Stock stock attractive at the current price?
The data as of Nov 10, 2026: price $0.1956, calculated fair value $0.2017 (+3%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. 20/20 Biolabs, Inc. currently trades 3% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of 20/20 Biolabs, Inc. (AIDX)?
The closing price on Nov 10, 2026 was $0.1956. Our estimate is $0.2017, about +3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with 20/20 Biolabs, Inc. Common Stock right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of 20/20 Biolabs, Inc.

How large is the market capitalisation of 20/20 Biolabs, Inc. (AIDX)?
The market capitalisation of 20/20 Biolabs, Inc. is $2.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of 20/20 Biolabs, Inc. (AIDX)?
The price-to-sales ratio of 20/20 Biolabs, Inc. is 1.43 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of 20/20 Biolabs, Inc. (AIDX)?
Earnings per share at 20/20 Biolabs, Inc. are $−0.7500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of 20/20 Biolabs, Inc. (AIDX)?
The return on equity (ROE) of 20/20 Biolabs, Inc. is −331% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of 20/20 Biolabs, Inc. (AIDX)?
On an EBIT basis the return on assets of 20/20 Biolabs, Inc. is −44.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of 20/20 Biolabs, Inc. (AIDX)?
The operating margin of 20/20 Biolabs, Inc. is −170% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at 20/20 Biolabs, Inc. (AIDX)?
Revenue at 20/20 Biolabs, Inc. is growing +36.5% versus a year earlier (3y avg −43.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does 20/20 Biolabs, Inc. (AIDX) generate?
The free cash flow of 20/20 Biolabs, Inc. is −$1.9B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does 20/20 Biolabs, Inc. (AIDX) carry?
The net debt of 20/20 Biolabs, Inc. is $258M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Continue in the live analysis

Fair value and trend for 40,000+ stocks, watchlist, comparison and the diversification check.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.